Unlocking the Therapeutic Potential of Mesenchymal Stromal Cell-Derived Extracellular Vesicles: A GMP-Compliant, Scalable Manufacturing Strategy

Human umbilical cord mesenchymal stromal cell-derived extracellular vesicles (hucMSC-EVs) emerge as promising nanotherapeutics for immunomodulation and tissue repair, yet their clinical translation has been constrained by critical manufacturing challenges in yield, stability, and batch-to-batch reproducibility. Here, we developed a Good Manufacturing Practice (GMP)-compliant, end-to-end platform integrating serum-free/xeno-free three-dimensional microcarrier culture with downstream tangential flow filtration and multimodal anion exchange chromatography. This integrated process achieved ultra-pure hucMSC-EVs [(1.96± 0.11) × 10⁹ particles/μg protein; 99.81% protein clearance] at 5.59 × 1013 particles per 15-L batch—sufficient for Phase I/II trials (400-subject trials at 0.50–1.40 × 10¹¹ particles/dose). Notably, our lyophilized formulation maintained EV structural integrity and biological activity under accelerated storage conditions at least for 3 months, effectively addressing stability challenges. Functionally, the dual immunomodulatory and regenerative capacities of hucMSC-EVs were demonstrated through both significant suppressions of phytohemagglutinin-induced peripheral blood mononuclear cell proliferation and dose-dependent stimulation of dermal papilla cell growth <i>in vitro</i>. Importantly, these cellular effects have been translated into therapeutic outcomes, with the EVs significantly promoting hair regeneration <i>in vivo</i>. This innovative manufacturing strategy holds great potential to accelerate the clinical translation of cell-free immune and regenerative therapies via leveraging hucMSC-EVs.